Loading…
Madrigal Pharmaceuticals, Inc. is projected to rise to $651.25 by 2027, a +23% move from its current price of $527.67. MDGL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $517.65 | $527.70 | $537.94 | +0.01% |
| May 30 | $513.57 | $527.72 | $542.26 | +0.01% |
| May 31 | $510.47 | $527.75 | $545.61 | +0.02% |
| Jun 1 | $507.88 | $527.78 | $548.46 | +0.02% |
| Jun 2 | $505.60 | $527.80 | $550.98 | +0.03% |
| Jun 3 | $503.56 | $527.83 | $553.27 | +0.03% |
| Jun 4 | $501.69 | $527.86 | $555.39 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $501.69 | $527.86 | $555.39 | +0.04% |
| Week 2 | $491.41 | $528.04 | $567.41 | +0.07% |
| Week 3 | $483.70 | $528.23 | $576.85 | +0.11% |
| Week 4 | $477.32 | $528.41 | $584.97 | +0.14% |
| Week 5 | $471.79 | $528.60 | $592.24 | +0.18% |
| Week 6 | $466.87 | $528.79 | $598.92 | +0.21% |
| Week 7 | $462.39 | $528.97 | $605.14 | +0.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Madrigal Pharmaceuticals, Inc. is a healthcare biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. The stock trades under the symbol MDGL.
Madrigal Pharmaceuticals, Inc. (MDGL) is a healthcare stock with current price $517.26 and a market cap of $11.93B. It is ranked 820 in market position.
The near-term forecast for 2026 shows NEUTRAL sentiment, with min $425.85, avg $517.26, max $683.30 and ROI 0.
From 2027 onward, the forecast envisions bullish momentum, with the avg price rising to $633.52 in 2027, $705.27 in 2028, $923.18 in 2029, and $1,067.65 in 2030. The outlook continues higher through 2035 (avg $1,812.91), 2040 (avg $2,518.87), and 2050 (avg $5,210.36), with the maxs reaching as high as $8,711.88.
A major floor 19.3% below — a decisive break under it would weaken the trend.
The nearest floor, 5.8% below — buyers have tended to step in here.
Price is pressing into resistance (2.3% away) — a breakout level to watch.
A major ceiling 7.0% above — clearing it would confirm fresh momentum.
Key MDGL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MDGL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $519.25 | Buy | $521.93 | Buy |
| MA 10 | $521.28 | Buy | $520.30 | Buy |
| MA 20 | $518.78 | Buy | $518.86 | Buy |
| MA 50 | $510.66 | Buy | $510.38 | Buy |
| MA 100 | $494.83 | Buy | $499.85 | Buy |
| MA 200 | $486.33 | Buy | $470.67 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.84 | Neutral |
| Stoch RSI (14) | 72.94 | Neutral |
| CCI (20) | 73.19 | Neutral |
| Williams %R (14) | -28.51 | Info |
| MACD (12,26,9) | -0.26 | Sell |
| ROC (12) | 3.46 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 71.49 | Neutral |
| TRIX (15) | 0.08 | Buy |
| Awesome (5,34) | -1.25 | Sell |
| Ultimate (7,14,28) | 52.86 | Neutral |
| Momentum (10) | 17.41 | Buy |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 521.32 | Buy |
| ADX (14) | 9.64 | Neutral |
| ATR (14) | 8.43 | Info |
The near-term technical picture is bullish, with RSI14 at 50 and moving averages showing upside support. The SMA50 is $507.34 and the SMA200 is $484.51.
Key levels to watch are a support at $497.03 and resistance at $539.89. The 30-day price range spans from $452.62 to $591.13, illustrating a constructive yet range-bound stance near the current level.
Annualized volatility stands at 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $425.85 | $527.67 | $692.54 | 0% | Neutral | |
| $531.34 | $651.25 | $836.01 | +23% | Bullish | |
| $581.17 | $725.60 | $956.23 | +38% | Bullish | |
| $747.42 | $947.62 | $1,275.24 | +80% | Bullish | |
| $860.22 | $1,105.49 | $1,514.47 | +110% | Bullish | |
| $870.79 | $1,132.89 | $1,576.60 | +115% | Bullish | |
| $957.60 | $1,260.09 | $1,778.69 | +139% | Bullish | |
| $1,025.80 | $1,364.28 | $1,950.83 | +159% | Bullish | |
| $1,148.85 | $1,543.38 | $2,233.49 | +192% | Bullish | |
| $1,391.55 | $1,887.43 | $2,762.02 | +258% | Bullish | |
| $1,870.72 | $2,648.64 | $4,063.50 | +402% | Bullish | |
| $3,608.98 | $5,488.94 | $9,033.21 | +940% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $425.85 | $527.67 | $619.45 | +0.00% |
| June 2026 | $460.48 | $537.33 | $639.30 | +1.83% |
| July 2026 | $451.62 | $530.10 | $636.77 | -1.35% |
| August 2026 | $452.51 | $533.58 | $645.71 | +0.66% |
| September 2026 | $465.81 | $551.35 | $671.25 | +3.33% |
| October 2026 | $467.97 | $555.83 | $680.42 | +0.81% |
| November 2026 | $462.17 | $550.62 | $677.27 | -0.94% |
| December 2026 | $469.08 | $560.48 | $692.54 | +1.79% |
Click any year to see its month-by-month MDGL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MDGL is projected to trade between $425.85 and $692.54, averaging $527.67 — a potential gain of 0% from today's $527.67. A consolidation phase looks the most probable path here.
Madrigal Pharmaceuticals, Inc.'s 2027 outlook centres on $651.25, within a $531.34 to $836.01 range. That is up +23% on the projected 2026 average. That marks a +23% change versus current levels. Momentum favours further upside here.
By 2028, MDGL could reach as high as $956.23, with a base case around $725.60 and support toward $581.17 — roughly +38% from $527.67. Buyers look set to stay in control over this stretch.
Expect MDGL to range from $747.42 to $1,275.24 through 2029. The $947.62 average target implies a +80% move from current prices. That is up +31% on the projected 2028 average. Momentum favours further upside here.
The MDGL price prediction for 2030 points to an average of $1,105.49 (low $860.22, high $1,514.47) — a potential gain of +110% on today's $527.67. Buyers look set to stay in control over this stretch.
In 2031, MDGL is projected to trade between $870.79 and $1,576.60, averaging $1,132.89 — a potential gain of +115% from today's $527.67. That is up +2% on the projected 2030 average. Momentum favours further upside here.
Madrigal Pharmaceuticals, Inc.'s 2032 outlook centres on $1,260.09, within a $957.60 to $1,778.69 range. That is up +11% on the projected 2031 average. That marks a +139% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MDGL could reach as high as $1,950.83, with a base case around $1,364.28 and support toward $1,025.80 — roughly +159% from $527.67. Momentum favours further upside here.
Expect MDGL to range from $1,148.85 to $2,233.49 through 2034. The $1,543.38 average target implies a +192% move from current prices. That is up +13% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The MDGL price prediction for 2035 points to an average of $1,887.43 (low $1,391.55, high $2,762.02) — a potential gain of +258% on today's $527.67. Momentum favours further upside here.
In 2040, MDGL is projected to trade between $1,870.72 and $4,063.50, averaging $2,648.64 — a potential gain of +402% from today's $527.67. That is up +40% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Madrigal Pharmaceuticals, Inc.'s 2050 outlook centres on $5,488.94, within a $3,608.98 to $9,033.21 range. That is up +107% on the projected 2040 average. That marks a +940% change versus current levels. Momentum favours further upside here.
Investing $1,000 in MDGL today (≈ 1.895124 MDGL) could be worth
$10,402.22
+$9,402.22 (+940%) by 2050 · US Dollar
Based on the average projected MDGL price of $5,488.94 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MDGLwould be worth at today's price.
$1,000 invested in MDGL on May 27, 2025 (≈ 3.682292 MDGL) would be worth
$1,943.03
+$943.03 (+94.3%) today · 1.94× · US Dollar
Based on a MDGL entry price of $271.57 vs. today's $527.67.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $513.47 | $1,027.66 | +2.8% |
| 1 month ago | $520.09 | $1,014.57 | +1.5% |
| 3 months ago | $445.85 | $1,183.51 | +18.4% |
| 6 months ago | $596.98 | $883.9 | -11.6% |
| 1 year ago | $271.57 | $1,943.03 | +94.3% |
| All time (5.0y) ago | $106.1 | $4,973.33 | +397.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MDGL forecast.
Our base-case forecast reaches $1,100.00 around 2030.
Implied market cap at $1,100.00: $25.36B
The multi-year forecast shows substantial upside. By 2030 the average price is projected at $1,067.65 with a min of $825.34 and a max of $1,475.10, and a forecasted ROI of 106.4. The bullish trajectory continues, with 2031 avg $1,089.28, 2032 avg $1,218.04, 2033 avg $1,310.59, 2034 avg $1,476.47, and 2035 avg $1,812.91, accompanied by rising ROIs (110.6, 135.5, 153.4, 185.4, 250.5 respectively).
By 2040, the avg price is projected at $2,518.87 with a max of $3,915.68 and ROI 387. By 2050, the avg price is $5,210.36, the min $3,365.82, the max $8,711.88, and ROI 907.3, all with bullish sentiment. These figures point to meaningful upside, tempered by the usual uncertainty around long-horizon forecasts.
Tap a question to reveal the answer.
Avg price $1,067.65; min $825.34; max $1,475.10; ROI 106.4; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising avg prices (2027 $633.52, 2028 $705.27, 2029 $923.18, 2030 $1,067.65; 2050 $5,210.36) and ROI up to 907.3, but 2026 is neutral.
Yes. The 2030 forecast has an avg price of $1,067.65 and a max of $1,475.10; the min is $825.34.
Current price $517.26; market cap $11.93B.
Avg $5,210.36; min $3,365.82; max $8,711.88; ROI 907.3; sentiment BULLISH.
Madrigal Pharmaceuticals, Inc. Community Discussion
0Share your Madrigal Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.